Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 46(2): 141-5, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1371651

ABSTRACT

The incidence and prevalence of histoplasmosis in Southeast Asia has not been extensively described. The first microbiologically documented case of disseminated histoplasmosis with cutaneous papulonodules in a 56-year-old woman from the Philippines is reported. She presented with fever and generalized papulonodular lesions in various stages, which evolved into vesicles with central necrosis that resembled molluscum contagiosum with an indurated erythematous halo. Biopsies revealed a granulomatous mass of lymphohistiocytic and epithelioid cells with intracellular budding yeast cells and dark nuclei. Cultures were positive for Histoplasma capsulatum. The patient was treated with amphotericin B (3 g) and 5-fluorocytosine (50 mg/kg/day), followed by ketoconazole (400 mg/day). Her clinical course was complicated by intractable hemolytic anemia that was initially treated with corticosteroids. A splenectomy was subsequently performed. Pneumonia and a brain abscess caused by Nocardia asteroides were secondary complications. Nine months after her admission, repeat testing was diagnostic for systemic lupus erythematosus. This patient serves to re-emphasize that cutaneous lesions in an immunocompromised patient must be evaluated by biopsy and culture analysis. Disseminated histoplasmosis in the immunocompromised host may present with unusual cutaneous lesions, and must be considered even in a nonendemic area.


Subject(s)
Dermatomycoses/microbiology , Histoplasmosis/pathology , Amphotericin B/therapeutic use , Dermatomycoses/drug therapy , Dermatomycoses/pathology , Female , Histoplasma/isolation & purification , Histoplasmosis/complications , Histoplasmosis/drug therapy , Humans , Immunocompromised Host , Ketoconazole/therapeutic use , Lupus Erythematosus, Systemic/complications , Middle Aged , Neutrophils , Philippines , Prednisone/therapeutic use
2.
Article in English | MEDLINE | ID: mdl-2528260

ABSTRACT

Melasma is a macular hypermelanosis of the sun-exposed areas of the face and neck. The clinical efficacy of azelaic acid (20%) and hydroquinone creams (2%) in the treatment of this benign pigmentary disorder was compared in a randomized, double-blind study with 155 patients of Indo-Malay-Hispanic origin. The creams were applied twice daily. A broad spectrum sunscreen was used concomitantly. Over a period of 24 weeks, 73% of the azelaic acid patients, compared with 19% of the hydroquinone patients, had good to excellent overall results, as measured by the reduction of melasma pigmentary intensity and lesion size. Transient mild to moderate irritant reactions were initially seen with both test drugs.


Subject(s)
Dicarboxylic Acids/therapeutic use , Hydroquinones/therapeutic use , Melanosis/drug therapy , Administration, Topical , Dicarboxylic Acids/administration & dosage , Dicarboxylic Acids/adverse effects , Double-Blind Method , Drug Eruptions/etiology , Female , Humans , Hydroquinones/administration & dosage , Hydroquinones/adverse effects , Male , Multicenter Studies as Topic , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...